Protalix BioTherapeutics (PLX) Misses Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.32 +0.87%
Revenue Growth %: -49.8%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
CRMT, More
Revenue Growth %: -49.8%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of ($0.22), $0.07 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $62.89 million versus the consensus estimate of $6.12 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank
- SWBI beats estimates by 71%, GEO nears 52-week high on policy tailwinds
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
